Fosun veteran Juxiang Xia joins Sparx Therapeutics
August 9, 2021
August 10th, 2021 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibody and antibody-drug conjugate (ADC) drugs, today announced the appointment of Ms. Juxiang
